Conference Coverage (IBC Protease Inhibitors)
Agouron Protease Inhibitor Enters Triple Combination Trials
Published in AIDS Weekly, July 8th, 1996
Nelfinavir mesylate (Agouron Pharmaceuticals Inc.) is the latest entry in what is now a field of four protease inhibitors being tested in combination with nucleoside-analog reverse-transcriptase inhibitors.
Early studies of nelfinavir in combination with stavudine (d4T) in patients with CD4 counts of at least 200 cells/(mu)L and HIV RNA levels of at least 15,000 copies/ml show that the drug decreases HIV RNA by 1.7 to 2.4 log10 and increases CD4 counts by 105 to 133 cells/(mu)L after two months of treatment.
"I think this is an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1996-07-08)
More Articles from AIDS Weekly
- Conference Coverage (IBC Protease Inhibitors)
Ritonavir Combinations Shine in Early Studies - Conference Coverage (IBC Protease Inhibitors)
Roche Researcher: Saquinavir Safe, Active in 3TC/AZT Combination - Conference Overview (XI Int Conf on AIDS)
AIDS Now A Manageable Disease - For Those Who Can Afford It - AIDS Therapies
Two Combination Regimens Shown To Be Advantageous in AIDS Patients - AIDS Therapies (Lamivudine)
Renal Dysfunction Affects Pharmacokinetics - AIDS Therapies (Viramune)
Accelerated Approval Received for Viramune - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
